Simplify Asset Management Inc. Makes New $8.35 Million Investment in United Therapeutics Corporation $UTHR

Simplify Asset Management Inc. purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 19,920 shares of the biotechnology company’s stock, valued at approximately $8,351,000. United Therapeutics accounts for about 0.2% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 16th largest holding.

A number of other institutional investors also recently modified their holdings of UTHR. Norges Bank bought a new stake in United Therapeutics during the 2nd quarter valued at $136,453,000. Invesco Ltd. grew its position in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Amundi lifted its holdings in United Therapeutics by 198.8% during the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after purchasing an additional 232,988 shares in the last quarter. Finally, Assetmark Inc. boosted its stake in United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.8%

Shares of UTHR stock opened at $502.90 on Tuesday. The business has a 50-day moving average price of $472.78 and a two-hundred day moving average price of $390.12. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99. The firm has a market cap of $21.65 billion, a P/E ratio of 19.06, a price-to-earnings-growth ratio of 5.04 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company earned $6.39 EPS. As a group, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $440.35, for a total value of $9,907,875.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 602,664 shares of company stock worth $279,087,286 over the last quarter. Company insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on UTHR shares. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. HC Wainwright upped their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Finally, Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $505.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.